Thrivent Financial for Lutherans Has $2.10 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Thrivent Financial for Lutherans lifted its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 217.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 415,262 shares of the company's stock after acquiring an additional 284,368 shares during the period. Thrivent Financial for Lutherans owned approximately 0.33% of Humacyte worth $2,097,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of HUMA. Commonwealth Equity Services LLC grew its position in shares of Humacyte by 27.0% during the 4th quarter. Commonwealth Equity Services LLC now owns 83,128 shares of the company's stock worth $420,000 after purchasing an additional 17,665 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in Humacyte during the fourth quarter worth approximately $177,000. Swiss National Bank increased its stake in Humacyte by 5.8% during the 4th quarter. Swiss National Bank now owns 172,100 shares of the company's stock worth $869,000 after acquiring an additional 9,400 shares during the period. HighTower Advisors LLC acquired a new position in Humacyte in the 4th quarter valued at $66,000. Finally, Endowment Wealth Management Inc. lifted its position in shares of Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock valued at $526,000 after acquiring an additional 3,590 shares during the period. 44.71% of the stock is owned by institutional investors.

Humacyte Stock Down 2.0 %

Shares of HUMA stock traded down $0.03 on Wednesday, reaching $1.46. The company had a trading volume of 4,873,406 shares, compared to its average volume of 3,446,236. The business's 50-day moving average is $3.43 and its 200 day moving average is $4.42. Humacyte, Inc. has a one year low of $1.31 and a one year high of $9.97. The stock has a market capitalization of $183.75 million, a PE ratio of -1.09 and a beta of 1.36.

Remove Ads

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. On average, sell-side analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HUMA has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Finally, Benchmark reissued a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of "Buy" and a consensus price target of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.